Cardiovascular and metabolic diseases continue to represent a leading global cause of morbidity, mortality, and healthcare burden. Cardiometabolic comorbidities—diabetes, obesity, CKD, metabolic dysfunction-associated steatohepatitis (MASH)—interact across the cardio‑kidney‑metabolic (CKM) spectrum and influence CV risk and therapeutic response. These conditions are multifactorial and interdependent, making early‑stage drug development particularly complex.
Save time and gain efficiency with end‑to‑end CVMD safety, metabolism, and regulatory integration. Our Early Phase Development Solution integrated approach to development guides you through the long and complex scientific and regulatory process to maximize the value of your asset. Through our dedicated team of scientific, regulatory, and program management advisors, we create a prospective plan to manage and communicate milestones, risk, and budgets to stakeholders and integrate insights across your program for smarter decision-making.
These studies help characterize GI tolerability, differentiate mechanisms, and complement cardiovascular and metabolic safety data to build a cohesive nonclinical package.
These studies help characterize GI tolerability, differentiate mechanisms, and complement cardiovascular and metabolic safety data to build a cohesive nonclinical package.
Labcorp supports CVMD development across diverse modalities, including small molecules, biologics, custom antibodies, cell therapies, gene therapies, and vaccines—as well as incretin-based therapies such as GLP-1 and GLP-1/GIP agonists.
Our global SEND team—active in CDISC SEND Consortium and FDA/PHUSE working groups—delivers compliant datasets and pathology workflows to streamline reviews.
We combine cardiovascular safety expertise, integrated nonclinical capabilities, and high‑fidelity data to reduce risk and enable confident IND-bound decisions.
When CVMD programs face complex cardiac safety questions, our people and our science move decisions forward. Labcorp’s experienced study directors and cross functional scientists work as an extension of your team—anticipating risks, shaping study designs, and interpreting cross disciplinary data to keep IND/CTA timelines on track.
